lirafugratinib (RLY-4008)

News alerts, weekly reports and conference planners

Company:

HLB Bio Group, Relay Therap

Drug class:

FGFR2 inhibitor

Related drugs:

FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	RLY-4008 Sensitive: C2 – Inclusion Criteria RLY-4008 Sensitive : C2	RLY-4008 Sensitive: C2 – Inclusion Criteria RLY-4008 Sensitive : C2
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	RLY-4008 Sensitive: C3 – Early Trials RLY-4008 Sensitive : C3	RLY-4008 Sensitive: C3 – Early Trials RLY-4008 Sensitive : C3
FGFR2 N549K	Endometrial Cancer	FGFR2 N549K	Endometrial Cancer	RLY-4008 Sensitive: D – Preclinical RLY-4008 Sensitive : D	RLY-4008 Sensitive: D – Preclinical RLY-4008 Sensitive : D

Associations
(3)